Grants & Awards Committee

The purpose of the ISHLT Grants & Awards Program is to support research training in heart and lung transplantation as well as end-stage heart and lung diseases so as to encourage the development of clinical or basic science research implications.

ISHLT members can log in to see contact information for each of the committee members and representatives listed below. Only ISHLT members have access to this information.

Headshot of Tereza Martinu

Tereza Martinu, MD, MHS (2026)

Chair
Toronto General Hospital/UHN
Toronto, Canada
Headshot of Kathleen Grady

Kathleen Grady, PhD, RN, MS, FAAN (2025)

Past Chair
Northwestern University
Chicago, IL USA
Headshot of David Peng

David Peng, MD (2026)

Member/ Advanced Heart Failure and Transplantation IDN Representative
University of Michigan
Ann Arbor, MI USA
Headshot of Alberto Benazzo

Alberto Benazzo, PhD (2025)

Member/ Advanced Lung Failure and Transplantation IDN Representative
Medical University of Vienna
Wien, Austria
Headshot of Bart Meyns

Bart Meyns, MD, PhD (2027)

Member/ Mechanical Circulatory Support IDN Representative
UZ Leuven
Leuven, Belgium
Headshot of Jean-Luc Vachiery

Jean-Luc Vachiery, MD (2027)

Member/ Pulmonary Vascular Disease (PAH & CTEPH) IDN Representative
HUB Hôpital Erasme
Anderlecht, Belgium
Headshot of Edward Horn

Edward Horn, PharmD (2025)

At Large Member
University of Pittsburgh
Pittsburgh, PA USA
Headshot of Arun Jose

Arun Jose, MD, MS (2027)

At Large Member
University of Cincinnati
Mason, OH USA
Headshot of Tim Pennel

Tim Pennel, MBChB, FC Cardio, PhD (2026)

At Large Member
University of Cape Town
Cape Town, South Africa
Headshot of Ciara Shaver

Ciara Shaver, MD, PhD (2027)

At Large Member
Vanderbilt University Medical Center
Nashville, TN USA
Headshot of Sue Bessner

Sue Bessner,

ISHLT Staff Liaison
ISHLT

Headshot of Megan Barrett

Megan Barrett,

ISHLT Staff Liaison
ISHLT
Chicago, IL USA

The purpose of the ISHLT Grants & Awards Program is to support research training in heart and lung transplantation as well as end-stage heart and lung diseases so as to encourage the development of clinical or basic science research implications.

Policies